Authors: Ullén, Anders¹; Lennartsson, Lena¹; Harmenberg, Ulrika¹; Hjelm-Eriksson, Marie¹; Kälkner, Karl Mikael¹; Lennernäs, Bo²; Nilsson, Sten¹

Source: Acta Oncologica, Volume 44, Number 6, September 2005 , pp. 644-650(7)

Publisher: Informa Healthcare

Abstract:

Once bone metastasized and androgen independent, prostate cancer is often associated with skeletal morbidity and disability. New treatment modalities that can palliate symptoms from the skeleton and inhibit further progression are warranted. In this study, the antitumoral effects following treatment with a combination of docetaxel and the new generation bisphosphonate, zoledronic acid, were investigated on two hormone-refractory prostate cancer cell lines: PC3 and DU145. The prostate cancer cells were treated with increasing concentrations of zoledronic acid in the absence or presence of docetaxel. Toxicity was measured using fluorometric microculture cytotoxic assay technique. A concentration of 25 µM, zoledronic acid reduced the viable cell number to 68% and 98% for PC3 and DU145 cells respectively. Docetaxel, on the other hand, at a concentration of 0.1 ng/ml, had no effect on the viability. However, a combination of zoledronic acid and docetaxel reduced the cell number to 60% and 81% respectively. Furthermore, zoledronic acid in the concentration range 12.5 µM–50 µM enhanced the antitumoral effects of docetaxel (0.01–1 ng/ml) in an additive and/or synergistic manner for both cell lines. These data support the hypothesis that zoledronic acid, in addition to having bone resorption inhibiting properties, also exhibits anti-tumoral effects. It also appears that combined treatment with docetaxel causes additive and/or synergistic cytostatic effects on prostate cancer cells.

Document Type: Research article

DOI: http://dx.doi.org/10.1080/02841860510029617

Affiliations: 1: Department of Oncology-Pathology Karolinska Institute, Stockholm, Sweden 2: Sahlgrenska Academy University of Gothenburg, Gothenburg, Sweden

Publication date: 2005-09-01

More about this publication?

• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Radiology & Imaging
• By this author: Ullén, Anders ;  Lennartsson, Lena ;  Harmenberg, Ulrika ;  Hjelm-Eriksson, Marie ;  Kälkner, Karl Mikael ;  Lennernäs, Bo ;  Nilsson, Sten

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers